Dr. Choy Tim Shing - Clinical Oncology
Specialist in Clinical Oncology
Highlights
- MCHK RegisteredVerified
- 1 LocationsTsim Sha Tsui
- Specialist in Clinical OncologyBachelor of Medicine and Bachelor of Surgery (MBBS) · Fellow of the Royal College of Radiologists · Fellow of the Hong Kong College of Radiologists · Medical degree 1991
- InsuranceBeing compiled|See details
About
Dr. Choy Tim Shing practises Clinical Oncology in Tsim Sha Tsui, Hong Kong.
Education
Specialist in Clinical Oncology
- Bachelor of Medicine and Bachelor of Surgery (MBBS)Bachelor of Medicine and Bachelor of Surgery (MBBS)1991
- Fellow of the Royal College of RadiologistsFellow of the Royal College of Radiologists1998
- Fellow of the Hong Kong Academy of Medicine (Radiology)Fellow of the Hong Kong Academy of Medicine (Radiology)2001
Hong Kong Academy of Medicine fellowships
- FHKCRFellow, Hong Kong College of Radiologists2001
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Locations
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Choy Tim Shing? Claim page and update insurance →
FAQ
Is Dr. Choy Tim Shing any good?
Dr. Choy Tim Shing practises Clinical Oncology in Tsim Sha Tsui, Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Choy Tim Shing do?
Dr. Choy Tim Shing practises in Clinical Oncology.
Where does Dr. Choy Tim Shing practise?
Dr. Choy Tim Shing practises at 安確腫瘤血液中心.
Are you Dr. Choy Tim Shing? Claim this page to update and manage.
ClaimResearch and publications
2 papers
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis.BMC cancer · 2018
- Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.BMC cancer · 2016
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer